Physician

Alyssa R Strazanac, MD

According to 2025 Medicare claims, Alyssa Strazanac, MD (NPI: 1588169460) practices rheumatology in the Greensboro-High Point, NC market, with the plurality of this provider's patient population coming from Guilford, NC. This provider's primary affiliated billing organization is GREENSBORO RHEUMATOLOGY, P.A. (NPI: 1497100721; TIN: 811945325) and primary practice location at 27410-9700. Strazanac is affiliated with the Triad HealthCare Network, LLC. (ACO ID: D0209), participating under the REACH model.

Strazanac's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 200 traditional Medicare patients, billed 35,239 HCPCS/CPT codes, and received $330,086 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 766 prescription claims across 181 beneficiaries totaling $325,679 in drug costs, led by Orencia Clickject (Abatacept). Open Payments data shows 202 records totaling $5,022. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$165K$330K2023 Medicare payment: $22,682 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $330,086 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/RN/RN/R
2023381,781$22,682
202420035,239$330,086

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$476K$953K2018 Drug cost: $4,601 (USD; Tot_Drug_Cst)2019 Drug cost: $36,578 (USD; Tot_Drug_Cst)2020 Drug cost: $27,553 (USD; Tot_Drug_Cst)2021 Drug cost: $227,246 (USD; Tot_Drug_Cst)2022 Drug cost: $952,754 (USD; Tot_Drug_Cst)2023 Drug cost: $684,256 (USD; Tot_Drug_Cst)2024 Drug cost: $325,679 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20182065$4,601
201972278$36,578
202071341$27,553
2021104397$227,246
2022127591$952,754
2023129572$684,256
2024181766$325,679

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99204New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more4444$110
96413Administration of chemotherapy into vein, 1 hour or less3449$94
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more66104$91
96365Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less5465$46
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's61126$12

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Orencia ClickjectAbatacept15420$85,096
OtezlaApremilast11330$53,775
Hydroxychloroquine SulfateHydroxychloroquine Sulfate15211,811$8,214
MethotrexateMethotrexate Sodium986,090$1,756
PrednisonePrednisone2228,336$1,289

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.202$5,022Novartis Pharmaceuticals Corporation
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Alyssa R. Strazanac, MD?

Tedicare shows public-source Medicare data for Alyssa R. Strazanac, MD (NPI 1588169460), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alyssa R. Strazanac, MD have ACO affiliation data?

Alyssa R. Strazanac, MD is shown with ACO affiliation data for Triad HealthCare Network, LLC. (REACH, ACO ID D0209).

What billing organization is linked to Alyssa R. Strazanac, MD?

Alyssa R. Strazanac, MD is linked to GREENSBORO RHEUMATOLOGY, P.A. (billing NPI 1497100721) in the available physician profile data.

Does Alyssa R. Strazanac, MD have Open Payments data?

Alyssa R. Strazanac, MD has 202 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.